Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 1, 2011, Pages 88-90

  Kanefendt, F ^a   Lindauer, A ^a   Kinzig, M ^b   Strumberg, D ^c   Scheulen, M E ^d   Mross, K ^e   Fischer, R ^f   Moritz, B ^g   Sorgel F ^b   Jaehde, U ^a  

^a UNIVERSITY OF BONN   (Germany)

^b IBMP   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g Central European Society for Anticancer Drug Research   (Austria)

Author keywords

Biomarker; Colorectal cancer; PK PD modeling; Sunitinib; VEGF

Indexed keywords

DRUG METABOLITE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PHARMACOLOGICAL BIOMARKER; SU 12662; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EXPOSURE; FEMALE; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PATIENT SATISFACTION; PREDICTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEX RATIO; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 78650817955     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP49088     Document Type: Conference Paper

References (7)

1. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007; 25: 4793-4799.
2. Lindauer A, Di Gion P, Kanefendt F, Tomalik-Scharte D, Kinzig M, Rodamer M et al. Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther. 2010; 87: 601-608.
3. Deprimo SE, Bello C. Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. Ann Oncol. 2007; 18 (Suppl): 11-19.
4. Houk BE, Bello CL, Kang D, Amantea M. Apopulation pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009; 15: 2497-2506.
5. Hormbrey E, Gillespie P, Turner K, Han C, Roberts A, McGrouther D et al. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis. 2002; 19: 651-663.
6. Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer. 2009; 9: 82.
7. Rini BI. Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions. Clin Cancer Res. 2007; 13: 1098-1106.